Treace Medical Concepts will announce Q1 2026 financial results on May 8, 2026, followed by a conference call.
Quiver AI Summary
Treace Medical Concepts, Inc. announced that it will release its financial results for the first quarter of 2026 on May 8, 2026, before market opening. Management will host a conference call at 8:00 am ET to discuss these results, with participants able to register for dial-in details. Treace focuses on improving surgical treatments for bunions and midfoot deformities, having developed the patented Lapiplasty®3D Bunion Correction® System. This innovative system addresses the underlying issues of bunions, which affect around 67 million Americans, and is complemented by other surgical systems aimed at various foot deformities. The company encourages investors to check its website for important updates and information about its products.
Potential Positives
- Treace Medical Concepts is set to release its financial results for the first quarter of 2026, indicating transparency and engagement with investors.
- The company is hosting a conference call to discuss financial results, allowing for direct communication with investors and potential queries.
- Treace continues to innovate within the medical technology field with its patented Lapiplasty®3D Bunion Correction® System, addressing a significant market need for bunion correction.
- The company is actively expanding its product offerings with additional systems and technology, indicating growth and potential for increased market share.
Potential Negatives
- There is no mention of expected financial performance or other specific metrics, which may raise concerns among investors about the company's financial health.
FAQ
When will Treace Medical release its 2026 financial results?
Treace Medical will release its financial results for the first quarter on May 8, 2026, before market open.
What time is the conference call for financial results?
The conference call to discuss financial results will begin at 8:00 am ET on May 8, 2026.
How can I participate in the Treace conference call?
Interested investors can register to receive dial-in numbers and a unique pin to join the call.
Where can I find the archived webcast of the conference call?
An archived webcast of the conference call will be available on Treace's investor relations website.
What solutions does Treace Medical offer for bunion treatment?
Treace Medical provides various systems, including Lapiplasty® and Adductoplasty®, for surgical management of bunion deformities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TMCI Revenue
$TMCI had revenues of $62.5M in Q4 2025. This is a decrease of -9.01% from the same period in the prior year.
You can track TMCI financials on Quiver Quantitative's TMCI stock page.
$TMCI Hedge Fund Activity
We have seen 52 institutional investors add shares of $TMCI stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 2,488,883 shares (-68.5%) from their portfolio in Q4 2025, for an estimated $6,097,763
- BANK OF AMERICA CORP /DE/ added 2,228,317 shares (+2593.9%) to their portfolio in Q4 2025, for an estimated $5,459,376
- GAGNON SECURITIES LLC added 2,091,311 shares (+67.2%) to their portfolio in Q1 2026, for an estimated $2,802,356
- JPMORGAN CHASE & CO removed 1,550,016 shares (-96.1%) from their portfolio in Q4 2025, for an estimated $3,797,539
- GAGNON ADVISORS, LLC removed 1,534,034 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,055,605
- DEUTSCHE BANK AG\ removed 680,769 shares (-73.1%) from their portfolio in Q4 2025, for an estimated $1,667,884
- CENTERBOOK PARTNERS LP removed 674,370 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,652,206
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TMCI Analyst Ratings
Wall Street analysts have issued reports on $TMCI in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Underweight" rating on 11/07/2025
To track analyst ratings and price targets for $TMCI, check out Quiver Quantitative's $TMCI forecast page.
$TMCI Price Targets
Multiple analysts have issued price targets for $TMCI recently. We have seen 5 analysts offer price targets for $TMCI in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Ben Haynor from Lake Street set a target price of $7.0 on 03/02/2026
- Rick Wise from Stifel set a target price of $3.0 on 01/07/2026
- Richard Newitter from Truist Securities set a target price of $3.0 on 12/18/2025
- Lilia-Celine Lozada from JP Morgan set a target price of $5.0 on 11/07/2025
- Danielle Antalffy from UBS set a target price of $5.85 on 11/07/2025
Full Release
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.
Investors interested in listening to the conference call may do so by registering . Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/ .
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at
www.treace.com
. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty
®
3D Bunion Correction
®
System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty
®
Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty
®
3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP
®
MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate
®
rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide™ patient specific, pre-op planning and cut guide technology. For more information, please visit
www.treace.com
.
To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram .
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
[email protected]
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
[email protected]
